• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
UK Pharmaceuticals and Healthcare Report Q3 2007 - Product Image

UK Pharmaceuticals and Healthcare Report Q3 2007

  • Published: October 2007
  • Region: United Kingdom, Great Britain
  • 86 pages
  • Business Monitor International


  • AstraZeneca
  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • MORE

The UK Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on the UKs pharmaceuticals and healthcare industry.

The UK drug sector is technologically advanced, modern and home to one of the best scientific communities in the world. However, as explained in the Q307 Pharmaceuticals & Healthcare Report, a lack of venture capital is stopping the British biotech industry from exploiting these advantages. According to industry estimates, the UK biotech industry is worth just GBP14bn (US$28.27bn), compared to a figure of US$392bn in the US.

As a whole, however, the UK pharmaceuticals market is strong. In 2006, pharmaceutical expenditure stood at US$26.1bn and over the forecast period this should grow at an impressive Compound Annual Growth Rate (CAGR) of 5.31%. Over this same period generic drugs should grow at a CAGR of 9.21%, suggesting that these products are acting as key drivers for the rest of the industry. Certainly the government is keen to encourage generic substitutions, while the refusal of the National Institute for Health & Clinical Excellence (NICE) to recommend National Health Service (NHS) coverage for many READ MORE >

Executive Summary
UK Pharmaceuticals & Healthcare Industry SWOT
United Kingdom Political SWOT
United Kingdom Economic SWOT
Business Environment Rankings
Western Europe Region
Business Environment Rankings
Business Environment Ranking
Economics - Long-Term Risk
Politics - Long-Term Risk
Regulatory Barriers
Domestic Sector Threat
Market Growth Potential
Market Size Ranking
Regional Focus
UK: Market Summary
Regulatory Regime
Intellectual Property Issues
Pricing and Reimbursement Issues
Table: NHS Price Comparisons For Major Pharmaceutical Markets
Industry Developments
Healthcare sector
Pharmaceuticals Industry
Foreign Sector
R&D Sector
OTC Sector
Retail Sector
Parallel Imports
Table: Savings From Parallel Imports In 2004 (EURmn)
Regional Developments
Health Tourism
Manufacturing Sector
Wholesale sector
Industry Forecast Scenario
Overall Market Forecast
Table: United Kingdom Drug Market Forecast Indicators
Key Growth Factors - Industry
Table: United Kingdom Research & Development (R&D) Forecast Indicators
Key Growth Factors - Macroeconomic
Table: United Kingdom - Macroeconomic Forecasts
Prescription Market Forecast
Table: United Kingdom Prescription Drugs Market Forecast Indicators
OTC Market Forecast
Table: United Kingdom OTC Market Forecast Indicators
Generics And Branded Market Forecasts
Table: United Kingdom Generics And Branded Market Forecast Indicators
Export/Import Forecasts
Table: United Kingdom Sectoral Trade Forecast Indicators
Company Profiles
Leading Multinational Manufacturers
Merck & Co
Leading Indigenous Manufacturers
Our Forecast Modelling
How We Generate Our Industry Forecasts
Technical Process
Pharmaceutical Industry

- AstraZeneca
- GlaxoSmithKline
- Merck & Co
- Novartis
- Pfizer
- Sanofi-Aventis

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos